London North West University Healthcare NHS Trust, Harrow, UK
London North West University Healthcare NHS Trust, Harrow, UK.
BMJ Open. 2024 Oct 26;14(10):e089125. doi: 10.1136/bmjopen-2024-089125.
Cystoscopy has revolutionised the process of diagnosing bladder cancer leading to better categorisation of risk levels and more precise treatment plans. Nonetheless, concerns arise about the lack of uniformity among observers in predicting tumour stage and grade. To address these concerns, artificial intelligence (AI) is being incorporated into clinical settings to aid in the analysis of diagnostic and therapeutic images. The subsequent report outlines a systematic review and meta-analysis protocol aimed at evaluating the effectiveness of AI in predicting bladder cancer based on cystoscopic images.
Our systematic search will use databases including PubMed, MEDLINE, Embase and Cochrane. The articles published between May 2015 and April 2024 will be eligible for inclusion. For articles to be considered, they must employ AI for analysis of cystoscopic images to identify bladder cancer, present original data and be written in English. The protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol 2015 checklist. Quality and bias risk across chosen studies will be evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 score.
Ethical clearance will not be necessary for conducting this systematic review since results will be disseminated through peer-reviewed publications and presentations at both national and international conferences.
CRD42024528345.
膀胱镜检查彻底改变了膀胱癌的诊断过程,有助于更好地分类风险水平和制定更精确的治疗计划。然而,观察者在预测肿瘤分期和分级方面缺乏一致性的问题仍然存在。为了解决这些问题,人工智能(AI)被纳入临床环境,以帮助分析诊断和治疗图像。随后的报告概述了一项系统评价和荟萃分析方案,旨在评估基于膀胱镜图像的 AI 预测膀胱癌的有效性。
我们的系统检索将使用包括 PubMed、MEDLINE、Embase 和 Cochrane 在内的数据库。符合条件的文章是 2015 年 5 月至 2024 年 4 月期间发表的文章。文章必须使用 AI 分析膀胱镜图像以识别膀胱癌,提供原始数据,并使用英文书写。本方案遵循 2015 年系统评价和荟萃分析报告的首选报告项目清单。使用诊断准确性研究的质量评估-2 评分评估所选研究的质量和偏倚风险。
由于本系统评价的结果将通过同行评审出版物和国内外会议上的演讲来传播,因此进行这项系统评价不需要伦理批准。
PROSPERO 注册号:CRD42024528345。